FDA approves Cobenfy for adults with schizophrenia
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...
Taking drugs like LSD and ecstasy can increase your risk of schizophrenia, according to new study
Psychedelics have been growing in popularity across North America for recreational and therapeutic use, with celebrities like ...
HealthDay on MSN1d
Psychedelics Like Psilocybin, MDMA Tied to Higher Odds for Schizophrenia
People are at higher risk of schizophrenia if they indulge in psychedelic drugs, a new study warns. Patients who land in the ER following hallucinogen use have a 21-fold higher risk of developing ...
Zacks.com on MSN3d
AbbVie Stock Declines as Schizophrenia Studies Fail, BMY Gains
AbbVie’s ABBV mid-stage studies of emraclidine for schizophrenia failed to meet their primary endpoint. Shares of the company ...
AbbVie Stock Slides on Schizophrenia Drug Study Failure
AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock ...
STAT4d
Risk of aspiration during surgery added to GLP-1 drug labels
The FDA updated GLP-1 drug labels to warn of the risk of patients breathing food into their lungs while under anesthesia for ...
Investing4d
AbbVie shares slip after schizophrenia drug trial misses primary endpoint
In October, AbbVie lifted his full-year income forecast, saying its was seeing "momentum" in its operations after ...